Physician

Katherine Bruya Reed, M.D.

According to 2025 Medicare claims, Katherine Reed, M.D. (NPI: 1396919569) practices dermatology in the Spokane-Spokane Valley, WA market, with the plurality of this provider's patient population coming from Spokane, WA. This provider's primary affiliated billing organization is DERMATOLOGY SPECIALISTS OF SPOKANE (NPI: 1912179599; TIN: 262158533) and primary practice location at 99202-1332. Reed is affiliated with the Health Connect Partners, LLC (ACO ID: A2342), participating under the MSSP model.

Reed's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 742 traditional Medicare patients, billed 8,753 HCPCS/CPT codes, and received $1,610,618 in Medicare payments. The top billing code was 17110 (Destruction of skin growth, 1-14 growths). Part D data shows 1,212 prescription claims across 377 beneficiaries totaling $1,038,553 in drug costs, led by Humira(Cf) Pen (Adalimumab). DME data shows 25 claims. Open Payments data shows 389 records totaling $837,420. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $166,671 to $1,610,618. Similarly, Part D prescription costs have moved sharply higher in recent years, from $63,426 to $1,038,553. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $160 to $9,053.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	885	5,016	$166,671
2016	1,017	6,224	$307,704
2017	1,007	10,280	$768,449
2018	1,022	12,799	$648,113
2019	995	7,648	$244,176
2020	811	6,013	$314,126
2021	767	5,513	$398,271
2022	824	8,118	$622,571
2023	855	7,809	$753,777
2024	742	8,753	$1,610,618

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	228	718	$63,426
2016	257	734	$101,712
2017	253	798	$146,996
2018	282	771	$168,533
2019	294	809	$237,652
2020	290	833	$249,287
2021	334	1,005	$212,302
2022	348	1,062	$220,523
2023	403	1,095	$366,765
2024	377	1,212	$1,038,553

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	12	$5,068
2022	N/R	49	$9,078
2023	N/R	35	$10,313
2024	N/R	25	$4,691

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
17110	Destruction of skin growth, 1-14 growths	247	285	$80
11102	Biopsy of related skin growth, first growth	146	165	$61
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	570	764	$58
17000	Destruction of precancer skin growth, 1 growth	317	407	$37
17003	Destruction of precancer skin growth, 2-14 growths	222	1,148	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	12	336	$192,779
Dupixent Pen	Dupilumab	39	1,048	$165,061
Taltz Autoinjector	Ixekizumab	14	392	$96,004
Dupixent Syringe	Dupilumab	12	336	$52,850
Clobetasol Propionate	Clobetasol Propionate	136	4,430	$6,581

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A6196	Alginate or other fiber gelling dressing, wound cover, sterile, pad size 16 sq. in. or less, each dressing	N	N/R	14	$3,542
A6252	Specialty absorptive dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing	N	N/R	11	$1,149

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	35	$706	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	354	$836,715	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Katherine Bruya Reed, M.D.?

Tedicare shows public-source Medicare data for Katherine Bruya Reed, M.D. (NPI 1396919569), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Katherine Bruya Reed, M.D. have ACO affiliation data?

Katherine Bruya Reed, M.D. is shown with ACO affiliation data for Health Connect Partners, LLC (MSSP, ACO ID A2342).

What billing organization is linked to Katherine Bruya Reed, M.D.?

Katherine Bruya Reed, M.D. is linked to DERMATOLOGY SPECIALISTS OF SPOKANE (billing NPI 1912179599) in the available physician profile data.

Does Katherine Bruya Reed, M.D. have Open Payments data?

Katherine Bruya Reed, M.D. has 389 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.